



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

13 Sep 2021 (#29)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Important Notices

[Partnerships for Enhanced Engagement in Research \(PEER\)](#). The United States Agency for International Development (USAID) and the National Academies of Sciences, Engineering and Medicine are pleased to announce that a call for new proposals for the PEER program is now open. This cycle will focus on sourcing locally led research projects from researchers in USAID partner countries that aid in our understanding of how shocks, such as the COVID-19 pandemic, affect key sectors in our partner countries and test approaches to help communities and sectors respond to and mitigate the effects of COVID-19 or similar future shocks. Projects funded under this year's call for applications will receive one-year awards of up to US \$70,000. In addition, they will receive personalized training and guidance from USAID's Research Technical Assistance Center on developing evidence-to-action plans and communications products. **The deadline for submission of pre-proposals is October 22, 2021.** Full proposal (by invitation only) deadline: January 28, 2022. For further details please review the [Request for Applications](#).

[NOT-CA-21-115](#) Notice of Pre-Application Webinar for the "Translational and Basic Science Research in Early Lesions (TBEL)" Program: RFA-CA-21-054 and RFA-CA-21-055. The National Cancer Institute (NCI) will hold a public pre-application teleconference on September 24, 2021, at 1:00-3:00 pm (ET) for the Translational and Basic Science Research in Early Lesions (TBEL) Funding Opportunity Announcements (FOAs):

- 1) [RFA-CA-21-054](#) - *Translational and Basic Science Research in Early Lesions (TBEL) (U54 Clinical Trial Not Allowed)*;
- 2) [RFA-CA-21-055](#) - *Translational and Basic Science Research in Early Lesions: Coordinating and Data Management Center (U24 Clinical Trial Not Allowed)*

NCI staff members involved in managing the TBEL program will provide technical assistance to potential applicants by explaining the goals and objectives of this initiative and answering questions from attendees.

Potential applicants are encouraged to submit their questions or comments to Dr. Elisa Woodhouse (woodhousee@mail.nih.gov) or Dr. Christos Patriotis (patriotisc@mail.nih.gov) in advance of the teleconference. Please include "NCI Technical Assistance Webinar for TBEL FOAs" in the subject line of the email.

Registration: Potential applicants interested in participating in the teleconference should use the provided registration link ([Register Here](#)) no later than 5:00 p.m. (ET), September 20, 2021.

[NOT-MH-21-340](#) Notice of Intent to Publish a Funding Opportunity Announcement: Effectiveness and Implementation Research for Post-Acute Interventions to Optimize Long-Term Mental Health Outcomes in Low- and Middle-Income Countries (R34 Clinical Trial Optional). The National Institute of Mental Health intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications for research on effectiveness and implementation research for post-acute interventions to optimize long-term mental health outcomes in low- and middle-income countries. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The FOA is expected to be published in October, 2021 with an expected application due date in December, 2021. This FOA will utilize the R34 activity code. Clinical trials will be optional.

[NOT-HL-21-015](#) Notice of Special Interest (NOSI): Promoting Cardiovascular and Cardiometabolic Health in Early Stages of the Lifecourse: Pre-adolescence Through Adolescence to Young Adulthood. This Notice of Special Interest (NOSI) calls for research to understand and promote cardiovascular and cardiometabolic health during transitional phases across the lifecourse, from pre-adolescence (6-10 years) through adolescence (11-18 years) to young adulthood (19-39 years). This initiative would support research to: 1) understand the mechanisms and the pathogenesis of cardiometabolic health and cardiovascular disease (CVD) risk in vulnerable groups throughout transitional phases from pre-adolescence into adolescence and adolescence into young adulthood, and 2) develop precision prevention interventions (at the individual and populations levels) to address cardiovascular and cardiometabolic risk across these transitional phases. This notice applies to due dates on or after October 5, 2021 and subsequent receipt dates through June 5, 2026. Submit applications for this initiative using one of the following funding opportunity announcements (FOAs).

- [PA-20-183](#) - NIH Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-185](#) - NIH Research Project Grant (Parent R01 Clinical Trial Not Allow)

[NOT-CA-21-113](#) Notice of Intent to Publish a Funding Opportunity Announcement for Research Bases for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network (UG1 Clinical Trial Required). The purpose of this Notice is to announce the NCI's intention to issue a Funding Opportunity Announcement (FOA) that invites applications for UG1(Cooperative Agreement)-funded Research Bases for the HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network. The 'CASCADE' Network seeks to conduct pragmatic clinical trials evaluating the effectiveness of clinically proven interventions to overcome barriers and reduce failures in the cervical cancer screening, management, and precancer treatment cascade for women living with HIV. The 'CASCADE' Network will be structured around three types of organizational units (funded by individual Cooperative Agreement grants): a single U24-funded Coordinating Center, up to three UG1-funded Research Bases, and up to eight UG1-funded Clinical Sites, all working collaboratively and in partnership with the NCI. The UG1 Research Bases will provide scientific and statistical leadership for developing and analyzing multi-institutional clinical trial concepts and protocols for implementation at multiple UG1 Clinical Sites, partner with the U24 Coordinating Center and the UG1 Clinical Sites to ensure compliance with human research participant protection and other regulatory and administrative reporting requirements, as well as work towards creating opportunities for training emerging investigators. This Notice is being provided to allow potential applicants sufficient time to develop responsive applications for UG1 (Cooperative Agreement)-funded Research Bases for the 'CASCADE' Network. The FOA is expected to be published in Fall 2021 with an anticipated application due date in late Winter 2021. Details of a planned pre-application webinar will be announced after the publication of the FOA. It is expected that the UG1 Research Base applicants will be self-organized multi-disciplinary teams co-led by US-based and/or LMIC-based PIs with complementary expertise in areas such as clinical effectiveness research, HPV/cervical cancer prevention and control, HIV/AIDS care, and gynecology/women's health/reproductive health issues. The NCI intends to fund up to three awards for the UG1 Research Bases. Estimated Award Ceiling: \$400,000 in direct costs per year for five years. Anticipated Eligible Organizations: Non-domestic (non-U.S.) Entity (Foreign Organization).

[NOT-CA-21-114](#) Notice of Intent to Publish a Funding Opportunity Announcement for Clinical Sites for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network (UG1 Clinical Trial Required) The purpose of this Notice is to announce the NCI's intention to issue a Funding Opportunity Announcement (FOA) that invites applications for UG1(Cooperative Agreement)-funded Research Bases for the HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network. The 'CASCADE' Network seeks to conduct pragmatic clinical trials evaluating the effectiveness of

clinically proven interventions to overcome barriers and reduce failures in the cervical cancer screening, management, and precancer treatment cascade for women living with HIV. The 'CASCADE' Network will be structured around three types of organizational units (funded by individual Cooperative Agreement grants): a single U24-funded Coordinating Center, up to three UG1-funded Research Bases, and up to eight UG1-funded Clinical Sites, all working collaboratively and in partnership with the NCI. The UG1 Research Bases will provide scientific and statistical leadership for developing and analyzing multi-institutional clinical trial concepts and protocols for implementation at multiple UG1 Clinical Sites, partner with the U24 Coordinating Center and the UG1 Clinical Sites to ensure compliance with human research participant protection and other regulatory and administrative reporting requirements, as well as work towards creating opportunities for training emerging investigators. This Notice is being provided to allow potential applicants sufficient time to develop responsive applications for UG1 (Cooperative Agreement)-funded Research Bases for the 'CASCADE' Network. The FOA is expected to be published in Fall 2021 with an anticipated application due date in late Winter 2021. Details of a planned pre-application webinar will be announced after the publication of the FOA. This FOA will utilize the UG1 activity code. The NCI intends to fund up to eight awards for the UG1 Clinical Sites. Estimated Award Ceiling: \$200,000 in direct costs per year for five years. Anticipated Eligible Organizations: Non-domestic (non-U.S.) Entity (Foreign Organization)

[NOT-DA-21-020](#) Notice of Special Interest (NOSI): Evaluation of sex differences on HIV-associated comorbidities in the context of stimulant use. The goal of this Notice is to encourage applications focusing on the understanding of the biological basis of sex differences in HIV neuropathogenesis and the comorbidity of HIV with misuse of stimulants, including amphetamine, methamphetamine, cocaine, and nicotine. Studies at single cell and CNS circuits levels and in live behaving animals are encouraged. This notice applies to due dates on or after February 5, 2022 and subsequent receipt dates through May 8, 2024. Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcement through the expiration date of this notice.

- [PA-20-183](#) - NIH Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-185](#) - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) – NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)

Funding Opportunity Announcements (FOA)

1. Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-21-322](#)

Type: R01

Application Due Date: October 05, 2021; February 05, 2022; June 05, 2022; October 05, 2022 to June 5, 2024. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants (R01) will support innovative studies designed to investigate biological/genetic bases of cancer health disparities, such as (1) mechanistic studies of biological factors associated with cancer health disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

2. Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-21-323](#)

Type: R21

Application Due Date: October 16, 2021; February 16, 2022; June 16, 2022; October 16, 2022 to June 16, 2024. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic research studies into the biological/genetic causes and mechanisms of cancer health disparities. These awards will support pilot and feasibility studies designed to investigate biological/genetic bases of cancer health disparities, such as (1) mechanistic studies of biological factors associated with cancer health disparities, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models and methods that are necessary to conduct basic research in cancer health disparities. In addition, the FOA will further the development of scientific areas, providing support for early-stage exploratory projects that lead to future in-depth mechanistic studies (such as R01 projects) of the biology of cancer health disparities.

Budget: The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. The total project period may not exceed 2 years.

3. Basic Research in Cancer Health Disparities (R03 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-21-324](#)

Type: R03

Application Due Date: October 16, 2021; February 16, 2022; June 16, 2022; October 16, 2022 to June 16, 2024. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These small research grants (R03) will support projects on cancer health disparities that can be carried out in a short period of time with limited resources. The projects should propose innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities.

Budget: Application budgets are limited to \$50,000 in direct costs per year. The total project period may not exceed 2 years.

4. Longitudinal Single Cell Characterization of ADRD Postmortem Tissue (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-22-029](#)

Type: R01

Application Due Date: October 05, 2021. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: The purpose of this funding opportunity is to support projects to identify cellular changes in ADRD post-mortem brain tissue across disease progression. Applicants are encouraged to propose single-nucleus transcriptomic and epigenomic studies that identify changes in neuronal, glial, or vascular cells over multiple ADRD stages, from early to mid-stage. All sequencing data and any available pre-mortem clinical data will be broadly shared with the research community.

Budget: NINDS intends to commit \$3.8M in total costs in FY2022 for up to four awards. Application budgets are limited to \$630,000 direct costs/year and need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

5. NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) Genetic Research Centers (GRCs) (U01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-DK-21-022](#)

Type: U01

Application Due Date: December 21, 2021. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) was established in July 2002 for the purpose of identifying genetic variation predisposing to Inflammatory Bowel Disease (IBD). Since its establishment and in collaboration with the International IBD Genetics Consortium, the NIDDK IBDGC has identified over 250 IBD susceptibility loci. However, for the great majority of these loci, the specific causal variants and effector genes have not yet been identified, and the biological mechanisms through which these variants influence IBD pathophysiology remain to be elucidated. The purpose of this Funding Opportunity Announcement (FOA) is to renew the IBDGC with a continued mission to characterize the genetic architecture of IBD phenotypes, particularly in populations currently underrepresented in IBD genomic studies, and to elucidate the biological mechanisms by which genetic variants influence IBD pathophysiology, phenotypes and clinical course. The Genetic Research Centers (GRCs) of the IBDGC will serve as sites for enrollment of IBD patients, relatives and healthy controls, for laboratory-based studies on biological samples obtained from these subjects, and for mechanistic studies of the risk variants identified, and of the genes, proteins and pathways they impact.

Budget: NIDDK intends to commit \$3,800,000 in FY 2022 to fund up to 7 awards. Application budgets are limited to \$375,000 direct costs per year. The maximum project period is 5 years.

6. Emerging Global Leader Award (K43 Independent Clinical Trial Required)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-21-251](#)

Type: K43

Application Due Date: November 3, 2021, November 3, 2022, and November 3, 2023. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: Reissue of [PAR-19-051](#). The purpose of the Fogarty Emerging Global Leader Award is to provide research support and protected time (three to five years) to an early career research scientist from a low- or middle-income country (LMIC) who holds a junior faculty position at an LMIC academic or research institution, as defined by the World Bank (<http://data.worldbank.org/about/country-classifications/country-and-lending-groups>), including "low-income," "lower-middle-income," and "upper-middle-income" countries). This intensive, mentored research career development experience is expected to lead to an independently funded research career at the LMIC institution or in another LMIC. This Funding Opportunity Announcement (FOA) invites applications from LMIC scientists from any health-related discipline who propose career development activities and a research project that is relevant to the health priorities of their country under the mentorship of LMIC and U.S. mentors. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA [PAR-21-252](#). See [Notices of Special Interest](#) associated with this funding opportunity. Applications for the K43 award must be submitted by academic education or research institutions in LMICs (as defined by the World Bank (<http://data.worldbank.org/about/country-classifications/country-and-lending-groups>); low-income, lower-middle-income, and upper-middle-income countries are included). FIC's Country Eligibility Notice ([NOT-TW-12-011](#)) "Notice of Change in Country Eligibility for Fogarty International Training Grants" applies to this FOA and states that for competing and re-competing research training grant applications (including the K43 mechanism), with the exception of Sub-Saharan African countries, FIC will no longer accept applications from, or applications that involve training of scientists from upper-middle-income countries that are also members of the G20 major economies <http://www.g20.org/en/members>.

For additional information see FIC's Country Eligibility page at <https://www.fic.nih.gov/Grants/Pages/country-eligibility.aspx>.

Budget: Award budgets are composed of salary and other program-related expenses, as described below. The total project period should be a minimum of 3 years and may not exceed 5 years. NIH will contribute up to \$75,000 (for a minimum of 75% effort or 9 person months) per year toward the salary of the career award recipient. NIH will contribute up to \$30,000 per year toward the research development costs of the award

recipient, which must be justified and consistent with the stage of development of the candidate and the proportion of time to be spent in research or career development activities. Salary for mentors, secretarial and administrative assistants, etc. is not allowed.

7. Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-21-252](#)

Type: K43

Application Due Date: November 3, 2021, November 3, 2022, and November 3, 2023. AIDS application dates: December 9, 2021, December 9, 2022, and December 11, 2023. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: Reissue of [PAR-19-098](#). The purpose of the Fogarty Emerging Global Leader Award is to provide research support and protected time (three to five years) to an early career research scientist from a low- or middle-income country (LMIC) who holds a junior faculty position at an LMIC academic or research institution, as defined by the World Bank (<http://data.worldbank.org/about/country-classifications/country-and-lending-groups>, including "low-income," "lower-middle-income," and "upper-middle-income" countries). This intensive, mentored research career development experience is expected to lead to an independently funded research career at the LMIC institution or in another LMIC. This Funding Opportunity Announcement (FOA) invites applications from LMIC scientists from any health-related discipline who propose career development activities and a research project that is relevant to the health priorities of their country under the mentorship of LMIC and U.S. mentors. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA [PAR-21-251](#). See [Notices of Special Interest](#) associated with this funding opportunity. Applications for the K43 award must be submitted by academic education or research institutions in LMICs (as defined by the World Bank (<http://data.worldbank.org/about/country-classifications/country-and-lending-groups>; low-income, lower-middle-income, and upper-middle-income countries are included). FIC's Country Eligibility Notice ([NOT-TW-12-011](#) "Notice of Change in Country Eligibility for Fogarty International Training Grants" applies to this FOA and states that for competing and re-competing research training grant applications (including the K43 mechanism), with the exception of Sub-Saharan African countries, FIC will no longer accept applications from, or applications that involve training of scientists from upper-middle-income countries that are also members of the G20 major economies <http://www.g20.org/en/members>.

For additional information see FIC's Country Eligibility page at <https://www.fic.nih.gov/Grants/Pages/country-eligibility.aspx>.

Budget: Award budgets are composed of salary and other program-related expenses, as described below. The total project period should be a minimum of 3 years and may not exceed 5 years. NIH will contribute up to \$75,000 (for a minimum of 75% effort or 9 person months) per year toward the salary of the career award recipient. NIH will contribute up to \$30,000 per year toward the research development costs of the award recipient, which must be justified and consistent with the stage of development of the candidate and the proportion of time to be spent in research or career development activities. Salary for mentors, secretarial and administrative assistants, etc. is not allowed.

8. Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-21-330](#)

Type: U01

Application Due Date: February 11, 2022; June 10, 2022; October 11, 2022 February 10, 2023 up to October 11, 2024. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and a onetime collection of buccal cells from both the screened and the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and other clinical data. This FOA supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers. The proposed research project must involve use of PLCO biospecimens and may include other resources; additionally, it should also take advantage of the unique characteristics of the PLCO biospecimens. Research on non-cancer outcomes, especially those related to aging (e.g., Alzheimer's, depression, hip fracture, osteoporosis and rheumatoid arthritis) may also be supported. Research projects that do not involve the use of PLCO biospecimens will not be supported under this FOA.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum period is 5 years.

9. AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAS-21-270](#)

Type: R03

Application Due Date: January 07, 2022; May 07, 2022; September 07, 2022 up to September 07, 2024. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: This funding opportunity announcement (FOA) seeks to facilitate the entry of both newly independent and early career investigators to the area of drug use and use disorder research and HIV/AIDS. This FOA, the AIDS-Science Track Award for Research Transition (A-START), encourages Small Research Grant (R03) applications to support research projects on drug use and/or use disorder and HIV/AIDS that can be carried out in a short period of time with limited resources. This FOA welcomes applications integrating substance use and/or substance use disorder (SUD) and HIV/AIDS across all areas of research supported by NIDA.

Budget: NIH intends to fund an estimate of 12 awards, corresponding to a total of \$1,000,000, for fiscal year 2022. Future year amounts will depend on annual appropriations. Budgets for direct costs of up to \$100,000 per year may be requested. The project period is limited to two years.

10. Pharmacokinetics (PK) and Pharmacodynamics (PD) of THC in Cannabis and Cannabis Products (R01 - Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-DA-22-028](#)

Type: R01

Application Due Date: February 09, 2022. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to support human and animal research on the pharmacokinetic (PK) and pharmacodynamic (PD) effects of Δ^9 -tetrahydrocannabinol (THC) that is present in cannabis and cannabis products. Applications testing a fully conceptualized premise founded with adequate preliminary data are appropriate for this FOA. Exploratory research projects should consider applying to the companion R21 announcement [RFA-DA-22-039](#).

Budget: NIDA has set aside \$2M in FY 2022 to support 4-8 awards in response to this FOA and the companion FOA. Application budgets are limited to \$500,000 in direct costs per year and need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

11. Pharmacokinetics (PK) and Pharmacodynamics (PD) of THC in Cannabis and Cannabis Products (R21 - Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-DA-22-039](#)

Type: R21

Application Due Date: February 09, 2022. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to support human and animal research on the pharmacokinetic (PK) and pharmacodynamic (PD) effects of Δ^9 -tetrahydrocannabinol (THC) that is present in cannabis and cannabis products. Exploratory projects are appropriate for this FOA. Applicants with projects testing a fully conceptualized premise founded with adequate preliminary data should consider applying to the companion R01 announcement [RFA-DA-22-028](#).

Budget: NIDA has set aside \$2M in FY 2022 to support 4-8 awards in response to this FOA and the companion FOA. The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. The maximum project period is 2 years.

12. High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-DA-22-040](#)

Type: R01

Application Due Date: February 15, 2022; August 15, 2022; February 15, 2023; August 15, 2023; February 15, 2024. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to support high priority research at the intersection of HIV and substance use. This FOA invites innovative research projects with the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention, treatment and cure of HIV among people who use drugs (PWUD). Applications submitted under this FOA are required to have a detailed research plan, preliminary data, and a clear description of the nexus with substance use. This FOA is open to both individual researchers and research teams and includes all areas of research from basic science to clinical and implementation research. All studies must focus on NIH HIV/AIDS Research Priorities: [NOT-OD-20-018: UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding](#).

Budget: NIDA intends to commit \$3.5 M in FY 2022, 2023, and 2024 to fund 3-5 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
[e: cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)
Stellenbosch University
2038 Wilcocks Building, Ryneveld Street
Enquiries: *Lizél*
[e: lizelk@sun.ac.za](mailto:lizelk@sun.ac.za) | t: +27 21 808 2105